Bristol-Myers Squibb Co.

bristol-myers squibb co. - All News and Analysis

• More Biotech Layoffs: Bristol-Myers Squibb, Entremed Feel the Pain

  Seeking Alpha - 2008-12-17

  Derek Lowe submits: I’m told by several people that Tuesday Bristol-Myers Squibb BMY is announcing layoffs in research and perhaps other areas. I don’t know how extensive these are, or how they’re spread across the New Jersey and Connecticut sites. What I do know is that accounting practices make...

  Tags: Biotech, Derek Lowe, Bristol-Myers Squibb Co., EntreMed Inc.

• Bristol-Myers Squibb Rep's Anti-Gay Marriage Donation Spurs Debate

  BNET - 2008-12-16

  A Bristol-Myers Squibb employee who donated money to campaigners in favor of California's Proposition 8 to ban gay marriage has caused controversy within the company -- or at least on the notoriously feisty Cafe Pharma bulletin boards. Drew Dellenbach identified himself as an employee of BMS when he made two...

  Tags: Bristol-Myers Squibb Co., Bristol-Myers Squibb Rep, Dellenbach, Sales Strategy, Sales Force Management, Sales, Jim Edwards

• Downturn Bites Into Cadbury Profit

  ReutersUK - 2008-12-16

  By David JonesLONDON (Reuters UK) - Confectionery giant Cadbury CBRY on Tuesday warned of slower growth and retailer destocking as the economic downturn starts to bite into the chocolate eating and gum chewing habits of consumers.The London-based company, maker of Dairy Milk chocolate, Trident gum and Halls cough drops, said...

  Tags: Cadbury Schweppes Plc., Food & Beverage, Operational Accounting, Manufacturing, Finance, Bristol-Myers Squibb Co., Oukbs

• Bristol Talks the Talk in Mandarin

  Seeking Alpha - 2008-12-13

  Mike Huckman submits: I was all set to write a blog today about Bristol-Myers Squibb BMY and a little-known company called Exelixis EXEL becoming the latest pharma-biotech hookup. Bristol-Myers Squibb is giving Exelixis nearly $200 million cash money up front to buy into a couple of cancer drugs. ...

  Tags: Healthcare, Mike Huckman, Bristol-Myers Squibb Co.

• Why a Pfizer Takeover of Bristol-Myers Squibb Seems Unlikely

  BNET - 2008-11-29

  Deutsche Bank analyst Barbara Ryan left pharma pholks with an interesting wishbone to chew on prior to Thanksgiving -- the notion that large pharma was overdue for consolidation and that Pfizer ought to consider finally merging with Bristol-Myers Squibb. It's not a new idea, of course. But is a Pfizer...

  Tags: Pfizer Inc., Bristol-Myers Squibb Co., BMS, Kindler, Mergers & Acquisitions, Corporate Law, Investment, Finance, Business Operations, Jim Edwards

• Bristol-Myers' Collaboration with Exelixis Is Looking Lucrative

  Seeking Alpha - 2008-11-24

  Eben Tessari submits: Exelixis announced that Bristol-Myers Squibb BMY has exercised its option to develop and commercialize Exelixis’ investigational new drug (IND) candidate XL413, a selective inhibitor of Cdc7. XL413 is a small molecule inhibitor of the serine-threonine kinase Cdc7. The function of Cdc7 is required for DNA replication...

  Tags: Healthcare, Eben Tessari, Bristol-Myers Squibb Co., Exelixis Inc.

• Bristol-Myers Squibb Plans $2.5 Bil. in Layoffs, Cuts

  BNET - 2008-11-13

  Bristol-Myers Squibb made a presentation this morning at the Credit Suisse Healthcare Conference that showed CFO John Marc-Huet wants to save the company $2.5 billion in "productivity initiatives." He's going to squeeze these out of "headcount and related costs" -- which sounds like a euphemism for layoffs. ...

  Tags: Layoff, Foreign-exchange, Pharmaceutical Company, Bristol-Myers Squibb Co., John Marc-Huet, BMS, Sales Strategy, Currency & Foreign Exchange, Sales Force Management, Strategy, Sales, Finance, Management, Jim Edwards

• Zacks Bull and Bear of the Day Highlights: Bristol-Myers Squibb, Cadence Design Systems, Amphenol, Cumulus Media and Wright Medical Group

  - 2008-10-24

  CHICAGO -- Zacks Equity Research highlights Bristol-Myers Squibb (NYSE: BMY) as the Bull of the Day and Cadence Design Systems (Nasdaq: CDNS) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amphenol Corp. (NYSE: APH), Cumulus Media Inc. (Nasdaq: CMLS) and Wright Medical Group (Nasdaq:...

  Tags: Amphenol, analysis, Bristol-Myers Squibb Co., Cadence Design Systems Inc., FINANCE, Investment, MARKETING, Nasdaq Stock Market Inc., New York Stock Exchange, newsletter, revenue, stock

• Bristol-Myers Squibb Co. Q3 2008 Earnings Conference Call Transcript

  Seeking Alpha - 2008-10-23

  Question-and-Answer SessionThank you. [Operator Instructions]. Okay guys, first question from Tim Anderson, with Sanford Bernstein. Tim Anderson - Sanford C. Bernstein Thank you. Couple of questions on the ImClone 11F8 product; what are the next steps to ascertain whether Bristol's rights to that? And regardless of who has right,...

  Tags: Data, Call Transcript, Earnings, Bristol-Myers Squibb Co., Research & Development, Business Operations, Seeking Alpha

• Earnings Preview: Bristol Myers Squibb

  Seeking Alpha - 2008-10-22

  Bristol Myers Squibb BMY is expected to report Q3 earnings before market open Thursday, October 23, with a conference call scheduled for 10:30 am EST. Guidance Analysts are expecting a profit of 42c on revenue of $5.23B. The consensus range for EPS is 38c to 43c, with a revenue range...

  Tags: Revenue, Earnings, Consensus, Bristol-Myers Squibb Co., Seeking Alpha, Sales Strategy, Operational Accounting, Sales Force Management, Sales, Finance, theflyonthewall.com, Healthcare

• BMS to Lilly re ImClone: "Thanks for the Cash, Suckers!"

  BNET - 2008-10-06

  Bristol-Myers Squibb CEO James M. Cornelius wrote this note today after the announcement that Eli Lilly and ImClone had agreed on the former's $6.5 billion, $70-a-share acquisition of the latter. Let's go through it line by line to see if there's a subtext, shall we? After describing...

  Tags: Eli Lilly & Co., Translation, Bristol-Myers Squibb Co., Lilly, ImClone, Biotechnology, Mergers & Acquisitions, Investment, Financial Accounting, Corporate Law, Finance, Business Operations, Jim Edwards

• The Lilly-ImClone Deal Worst-Case Scenario

  BNET - 2008-10-02

  Some people were apparently surprised that Eli Lilly has emerged as the mystery $70-a-share bidder for ImClone. BNET readers weren't among them, as I noted a few days ago this is just the kind of bold plan that CEO John Lechleiter seems to favor. Interestingly, ImClone's stock...

  Tags: Asset, Bristol-Myers Squibb Co., ImClone, Lilly, BMS, Asset Management, Operational Planning, Business Operations, Jim Edwards

• Predictions on Imclone's Suitors

  Seeking Alpha - 2008-09-28

  Derek Lowe submits: So it seems that Bristol-Myers Squibb BMY took my advice (yeah, sure) and made an insultingly incremental counteroffer for Imclone IMCL , raising their $60/share all the way to. . .$62. I was hoping for something more like $60.25 myself, but you can’t have everything (I...

  Tags: Biotech, Bristol-Myers Squibb Co., ImClone Systems Inc.

• BMY Ups the Ante on ImClone

  Seeking Alpha - 2008-09-23

  Mike Havrilla submits: Last night, Bristol-Myers BMY announced plans to increase its bid for the remaining 83% of ImClone Systems IMCL that it does not already own, to $62 per share, and plans to take the offer directly to shareholders in the form of a tender offer. ImClone and Chairman...

  Tags: ImClone Systems Inc., Biotech, Healthcare, Bristol-Myers Squibb Co.

• Bristol-Myers Raises ImClone Offer to $62

  Seeking Alpha - 2008-09-23

  Ron Haruni submits: In a letter send Monday to Carl Ichan, the Chairman of ImClone Systems IMCL, Bristol-Myers Squibb BMY, announced that after consulting with external financial advisors, the company has concluded that its initial $60 per share all cash offer made two months ago for ImClone was inadequate. Therefore,...

  Tags: ImClone Systems Inc., Biotech, Bristol-Myers Squibb Co.

• Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share

  - 2008-09-22

  NEW YORK -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that it is increasing its initial offer for ImClone Systems Incorporated (NASDAQ: IMCL) and intends to commence a tender offer for the currently outstanding shares of common stock of ImClone that are not already owned by Bristol-Myers Squibb for $62.00...

  Tags: Bristol-Myers Squibb Co., Company, FINANCE, ImClone Systems Inc., Investment, SEC

• Bristol-Meyers Squibb vs. Imclone: Icahn Stirs Up the Pot

  Seeking Alpha - 2008-09-14

  Derek Lowe submits: I haven’t mentioned the attempt by Bristol-Meyers Squibb BMY to buy out Imclone IMCL until now. The reasons for the move are unsurprising – BMS would like all the revenue from Erbitux, instead of just a share of it, and sees some value coming up in...

  Tags: Biotech, Bristol-Myers Squibb Co., ImClone Systems Inc.

• Status Report: ImClone Systems - Bristol-Myers Squibb

  Seeking Alpha - 2008-09-13

  The M & A Researcher submits: On Thursday, September 11, Bristol-Myers Squibb BMY  issued this letter to ImClone Systems IMCL in response to IMCL's offer rejection. Excerpts include the following: As you know, Bristol-Myers holds the exclusive, long-term marketing rights in the United States to ERBITUX® and related...

  Tags: ImClone Systems Inc., Bristol-Myers Squibb Co., Healthcare

• Ownership of Erbitux Follow-On Is Central to ImClone Takeover

  Seeking Alpha - 2008-09-13

  EP Vantage submits: The escalating squabble between Bristol-Myers Squibb BMY and ImClone Systems IMCL over ownership of the potentially valuable Erbitux follow-on, IMC-11F8, is likely to be a big factor in determining whether a third party makes a firm offer for the US biotech. A look at...

  Tags: Healthcare, Bristol-Myers Squibb Co., ImClone Systems Inc.

• Summer Surge for Pharma Powers IHE, but Concerns Remain

  Seeking Alpha - 2008-09-11

  Don Dion submits: Buoyed by some consolidation and seen as a safe haven in an uncertain market, healthcare stocks rallied hard in July and held their momentum into August. The sector cooled some during the last few weeks, but the S&P 500’s healthcare companies were still up...

  Tags: Healthcare, ETF, Abbott Laboratories Inc., Allergan Inc., Bristol-Myers Squibb Co., Barr Pharmaceuticals Inc., Johnson & Johnson, Eli Lilly & Co., Merck & Co. Inc., Pfizer Inc., Schering-Plough Corp., Wyeth

• Incorporated: 1933
• CEO: Mr. James M. Cornelius